Please login to the form below

Not currently logged in

HER2 inhibitor

This page shows the latest HER2 inhibitor news and features for those working in and with pharma, biotech and healthcare.

Strong five-year survival data for Kisqali in breast cancer

Strong five-year survival data for Kisqali in breast cancer

Novartis’ Kisqali plus letrozole offers more than a year survival benefit for postmenopausal women with HR+/HER2 advanced breast cancer. ... Kisqali is approved in the US and EU as initial endocrine-based therapy in combination with an aromatase

Latest news

More from news
Approximately 2 fully matching, plus 18 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Acquisition company. 628. Cascadian Therapeutics/Seattle Genetics. Lead programme tucatinib, oral, small molecule TKI highly selective for HER2 (p2). ... This acquisition brings tucatinib, an oral tyrosine kinase inhibitor that is highly selective for

  • Deal Watch table for December 2014 Deal Watch table for December 2014

    440. OncoEthix / Merck &Co. Lead product oral BET inhibitor, OTX015 for oncology indications (p1b). ... ONT-380 (ARRY-380), oral, reversible and selective small molecule HER2 inhibitor (p1).

  • Pharma deals during April 2014 Pharma deals during April 2014

    GSK's recently approved MEK inhibitor Mekinist and BRAF inhibitor Tafinlar will position Novartis to become a leader in the potential blockbuster market for metastatic melanoma, neglected by their current portfolio. ... Additional GSK products include

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Subscribe to our email news alerts

Featured jobs


Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

Box 1
Strategic commitment
KOL Ambassador Program & Podcast Creation: A Customer Story
Animation: Living With
The journey from the patient's perspective...